Please enter mandatory and valid details

Media

OptraSCAN Launches a Comprehensive Image Management and Image Storage Solution with Multiple Adoption Tiers

OptraSCAN Launches a Comprehensive Image Management and Image Storage Solution with Multiple Adoption Tiers

OptraSCAN®, the leading end-to-end digital pathology solution provider, announces the introduction of a combined Image Management and Image Storage Solution, to enable and simplify the digital transformation of pathology laboratories. The OptraSCAN IMAGEPath™ image management system is an open platform that can easily integrate with scanners from multiple manufacturers and over 20 different image formats, in addition to being compatible with external 3rd-party AI applications for pathology. The combined offer includes image management and 50 GB to 100 TB of storage with multiple adoption tiers at an extremely affordable monthly subscription fee. This provides the flexibility to fit the needs of a wide range of users — from one single pathologist to large, enterprise-level solutions.

Managing, accessing, and sharing images can be costly and complex. The IMAGEPath™ image management solution was designed by pathologists to simplify digital pathology workflows. It includes a conferencing feature for real-time synchronized or asynchronous review of a case, for online collaborations and second opinions from remote pathologists. Smart features, such as case prioritization and audit trail, and the ability for users to customize the user interface to optimize lab operations and efficiency are also included. The result is enhanced productivity and the enablement of improved health outcomes.

"Now that we have addressed the data acquisition challenge with our affordable digital scanners, we are looking beyond this to address the challenges of image management, storage and access," says Abhi Gholap, OptraSCAN Founder & CEO. "We designed our solution to simplify image management and image storage at a very compelling price point. We can address the needs of a single researcher, with a few images to share, all the way to a large institution, where an open system provides the flexibility and interoperability they need. We have included features to enable telepathology, case management, analytics framework, user authentication and audit trail."

OptraSCAN has incorporated and added features to IMAGEPath in response to feedback from users all over the world. This flexible and open platform has features addressing the needs of pathologists, pharma partners, AI partners and academic research centers. OptraSCAN remains committed to innovation and the relentless pursuit of excellence, to offer compelling and affordable solutions.

About OptraSCAN, Inc.

OptraSCAN® has 5 patents on its devices, AI analytics and cloud streaming platforms. OptraSCAN has received CE-IVDR and is being used in more than 100 sites globally. Headquartered in California, OptraSCAN has over 23 distributors in USA, UK, Denmark, Italy, Greece, France, Morocco, Russia, China, India, UAE, South Korea, Singapore, and Japan.

Please visit www.optrascan.com

Media Inquiries Contact

Arnol Rios | Global VP, Sales, | +1 (408) 524 5300 | M +1 (781) 975 4623
Email: arnol@optraventures.com

OptraSCAN Empowers AIG Hospitals with Digital Pathology Solutions

OptraSCAN Empowers AIG Hospitals with Digital Pathology Solutions

Hyderabad (Telangana) [India], August 8: OptraSCAN, a global leader in digital pathology solutions, is delighted to announce the successful implementation and utilization of its high-speed Digital Pathology Platform OS-Ultra by AIG Hospitals (A unit of Asian Institute of Gastroenterology), Hyderabad. This partnership marks another mile stone in Optra SCAN's commitment to revolutionizing the field of digital pathology and empowering health care organizations worldwide.

AIG Hospitals, are owned multidisciplinary institution headed by Chairman Dr. Duvvur Nageshwar Reddy, has chosen Optra SCAN's cutting-edge digital pathology platform OS Ultrato revolutionize their diagnostic processes, enable advanced AIbased analytics, optimize workflows, and drive innovation within their pathology practices. The OptraSCAN scanner OS-Ultrawas unveiled at the inauguration of AIGHospitals' Pathology department, marking a significant milestone for AIG Hospitals in advancing their pathology practices.

Dr. Anuradha Sekaran, Director and Chief of Pathology at AIG expressed their excitement, stating, 'Our primary objective is to deliver the highest quality diagnosis to our patients, and the adoption of OptraSCAN's digital pathology solution is a significant step in that direction. It enable susto optimize workload distribution, facilitate instants pecia list opinions,enable remote case reviews, and simplify tumor board joint reviews.The main motive of digitizing pathology is to use Artificial Intelligence as a modality in routine diagnostic work and promote research activities. OptraSCAN's whole slide scanners are both affordable and efficient, providing excellent imag equality.

We are delighted to welcome AIG Hospitals to our growing family of customers,' said Abhi Gholap, Founder and CEO at OptraSCAN. 'Their decision to partner with OptraSCAN under scores the trust our customers place in our digital pathology solutions. We look forward to collaborating closely with AIG Hospitals and supporting the min their mission to deliver exceptional patient care.' OptraSCAN remains committed to delivering innovative digital pathology solutions that empower healthcare institutions worldwide. With a strong track record of success and a dedication to advancing the field of pathology, OptraSCAN continues to be a trusted partner in improving diagnostic accuracy, enhancing workflows, and driving transformative change in pathology practices.

OptraSCAN is a global leader in providing end-to-end digital pathology solutions, empowering healthcare institutions to transition from traditional glass slides to digitize dimages for improved diagnostics, research, and education. OptraSCAN's innovative technology, including high-speed whole slide scanners, image analysis software, and data management tools, enables pathologists to make more accurate and timely diagnosis.

For more information about OptraSCAN, please visit www.optrascan.com.

AIG Hospitals is a top gastroenterology hospital in Hyderabad, India, offering advanced medical services and cutting-edge TelePathology for remote evaluation. It features an 800-bed super specialty facility and a comprehensive Lab Medicine department for accurate reports 24/7.The hospital has a strong academic focus, training over 90 DNB doctors and publishing more than 430 research papers.

For more information about AIG,visit www.aighospitals.com.

Lumea and OptraSCAN Announce Partnership to Enable Seamless Adoption of Digital Pathology

Lumea and OptraSCAN Announce Partnership to Enable Seamless Adoption of Digital Pathology

Lumea, the leader in integrated digital pathology, & OptraSCAN, the top end-to-end digital pathology solution provider, announced a collaboration agreement.

LEHI, UTAH, UNITED STATES, April 27, 2023/EINPresswire.com/ — Lumea, a global leader in integrated digital pathology solutions, and OptraSCAN, a leading end-to-end digital pathology solution provider, today announced a strategic commercial collaboration agreement. This agreement brings together Lumea’s comprehensive digital pathology platform with a wide range of digital scanning solutions to enable providers to adopt digital pathology efficiently and cost-effectively.

Lumea combines unique tissue-handling technology with digital technology to create efficiencies for the surgery center, lab, and pathologists, and bring a return on investment to digital pathology.

OptraScan has developed a wide range of digital pathology scanners for small, medium, and large high-volume laboratories with Brightfield, Fluorescence, and Frozen Section for Live View in surgery suites. All products are designed from the ground up to produce high-quality images at a cost-effective price point.

The Lumea-OptraSCAN partnership will enable the following: Seamless adoption of Lumea’s workflow solutions and AI along with OptraScan’s digital scanners tailored to the needs of a wide range of customers Multiple options for leasing, purchasing, or pay-on-demand commercial agreements to find the best financial option for every customer A framework for global collaboration with partners to enable better patient management, increased innovation, and ultimately better outcomes for everyone

“OptraScan set out on a mission to disrupt the digital pathology marketplace by providing high-quality solutions accessible to everyone and reducing the barriers to entry,” said Abhi Gholap, OptraSCAN’s CEO and Co-Founder. “Lumea’s commitment to innovation and quality resonates with the values of OptraSCAN, and we share a common goal to enable wide adoption of digital pathology.”

“Lumea is revolutionizing the way companies adopt and implement digital pathology and we are thrilled to work side by side with OptraSCAN assisting users with the highest quality solutions to improve the ability to read digitally.” said James Thackeray, Lumea Chief Commercialization Officer.

OptraScan and Lumea are also both sponsors of the Digital Diagnostic Summit, a collaborative event where the leaders in digital pathology implementation come together to break down adoption barriers and advance technology throughout the entire pathology workflow. The event will take place September 17-19 in Park City, Utah. Registration is limited to 150 attendees here: digitaldiagnosticsummit.com

About OptraSCAN, Inc OptraSCAN® are pioneers in the On-Demand Digital Pathology® System, focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services. An ISO 13485-certified company and CE-marked whole slide scanners for IVD use, OptraSCAN is working to eliminate the barriers to “Go Digital” no matter the size of the pathology lab, the lab’s throughput, or global location.

OptraSCAN’s end-to-end digital pathology solution provides effective acquisition of whole slide images, viewing, storing, real-time sharing, reporting, and AI & ML based Image analysis solutions via On-Demand or outright purchase model.

About Lumea

Lumea leverages preanalytic technology to make digital pathology both viable and valuable by improving biopsy handling, tracking, workflow, and diagnosis. Our tech results in measurably better tissue quality, efficiency, cost and time savings, and increased tissue yield on slides. Our unique Lumea+ platform integrates with any LIS and includes marketplace partner diagnostic AI, scanner, and genetic testing partners. To learn more about the benefits of using Lumea’s technology, please visit lumeadigital.com

Media Inquiries Contact

Arnol Rios | Global VP, Sales, | +1 (408) 524 5300 | M +1 (781) 975 4623
Email: arnol@optraventures.com

Bianca Collings | VP Marketing, Lumea | +1 (206) 617-4785
Email: bianca@lumeadigital.com

Paige, OptraScan Partner to Improve Digital Pathology Integration

Paige, OptraScan Partner to Improve Digital Pathology Integration

Paige and OptraSCAN have announced a partnership to streamline the adoption of digital pathology technology in the United States, European Union countries and United Kingdom.

The two companies aim to reduce barriers to digitising glass pathology slides, which will in turn enhance workflows in pathology and oncology.

Together, the companies will integrate Paige’s clinical AI applications and interoperable enterprise imaging platform with OptraSCAN’s digital pathology scanner to offer advanced end-to-end digital pathology workflow solutions. This provides a streamlined path for pathologists to adopt Paige’s leading suite of digital pathology applications, including the FullFocus whole-slide image viewer and AI applications including Paige Prostate Suite and Paige Breast Suite alongside OptraSCAN’s affordable digital pathology scanners. OptraSCAN devices have 15 to 480 slide loading capabilities that digitise the glass slides at 40x in less than one minute per slide with patented composite imaging offering.

“We are excited to work with OptraSCAN to make it easier for laboratories and healthcare networks around the world to adopt digital pathology workflows,” said Andy Moye, PhD, Chief Executive Officer at Paige. “This collaboration is an important step in our mission to unlock the full potential of AI in routine clinical use and provide healthcare professionals with precise insights to help patients get the most effective care.”

Abhi Gholap, Founder and CEO of OptraSCAN said, “OptraSCAN’s mission to enable pathology slide digitisation at fractional costs is eventually resulting into higher market demand for digital pathology applications. This partnership with Paige will facilitate adoption of digital infrastructure for global clinical and molecular pathology community in an efficient way.”

About Paige

Paige is using the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment options for patients and design new biomarkers for drug development so that every patient gets precise treatment options.

For additional information, please visit: https://www.Paige.ai, Twitter and LinkedIn.

About OptraSCAN, Inc.

OptraSCAN® are pioneers in the On-Demand Digital Pathology® System, focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services. An ISO 13485 certified company and CE marked whole slide scanners for IVD use, OptraSCAN is working to eliminate the barriers to “Go Digital” no matter the size of the pathology lab, the lab’s throughput or global location.

OptraSCAN’s end-to-end digital pathology solution provides effective acquisition of whole slide images, viewing, storing, real-time sharing, reporting and AI & ML based Image analysis solutions via On-Demand or outright purchase model.

Please visit www.optrascan.com

Media Inquiries Contact

Arnol Rios | Global VP, Sales, | +1 (408) 524 5300 | M +1 (781) 975 4623
Email: arnol@optraventures.com

OptraSCAN launches OnDemand Digital Pathology

OptraSCAN launches OnDemand Digital Pathology

OptraSCAN®, the leading end-to-end digital pathology solution provider announces the introduction of OnDemand Digital Pathology® solution to meet today’s need for complete digital transformation of pathology laboratories in North America. Laboratories and Hospitals can save hundreds of thousands of dollars spent on Capital purchases by subscribing to OptraSCAN OnDemand Digital Pathology® for a low monthly fee.

OptraSCAN OnDemand Digital Pathology® subscription service will offer OptraSCAN whole slide digital scanners (Brightfield / Fluorescence) with 15-480 slide loading capacity, scanning in about 58 seconds at 40x, a high-end workstation pre-loaded with workflow software, a Telepathology application, and AI analytics packages for IHC / Morphology / Immunofluorescence and Cytology, plus Microsoft Azure Cloud storage and 24×7 support and services.

Speaking at the United States and Canadian Academy of Pathologists (USCAP) Annual Meeting in New Orleans, (Booth #404), Abhi Gholap, Founder and CEO, OptraSCAN said, “Pathology is a cost-conscious market and the current requirement to invest $300–$500k to adopt digital pathology has limited its adoption over the last two decades. With no upfront costs, OptraSCAN scanning devices are compact, easy to install and operate. We ship them to your doorstep and manage them remotely with our 24×7 support infrastructure. We also ensure a 99.99% uptime. With our complete solution to scan, store, share and analyze pathology and cytology images, you can leave your infrastructure worries to us. We will manage, monitor, and deliver to your satisfaction for a low monthly fee. We are getting tremendous market traction with our Year-Over-Year revenues growing at 274% serving the Histopathology and Cytopathology markets.”

About OptraSCAN, Inc.

OptraSCAN has 5 patents on its devices, AI analytics and cloud streaming platforms. OptraSCAN has received CE-IVDR and used at more than 100 sites globally including developing world countries like India, South Africa, and Brazil. Headquartered in California, OptraSCAN has over 23 distributors in USA, UK, Denmark, Italy, Greece, France, Morocco, Russia, China, India, UAE, South Korea, Singapore and Japan.

Media Inquiries Contact

Arnol Rios | Global VP, Sales, | +1 (408) 524 5300 | M +1 (781) 975 4623
Email: arnol@optraventures.com

OptraSCAN's OS-SiA Artificial Intelligence-Equipped Digital Pathology Scanner Obtained US Patent for Simultaneous Tissue Area Scanning, Indexing and Analysis

OptraSCAN's OS-SiA Artificial Intelligence-Equipped Digital Pathology Scanner Obtained US Patent for Simultaneous Tissue Area Scanning, Indexing and Analysis

OptraSCAN®, the main end-to-end digital pathology resolution supplier, introduced its digital pathology scanner OS-SiA has been granted US patent – No 2020/0334814 A1 by the USA Patent and Trademark Workplace. OS-SiA has inbuilt intelligence to scan, index and analyze pathological samples concurrently. This can profit the end-user to view the entire slide scanned picture together with analyzed output as an overlay throughout their assessment course of.

OptraSCAN’s digital pathology scanner OS-SiA

The patent describes a method invented by OptraSCAN, the AI-enabled digital pathology scanner OS-SiA routinely identifies specimens to scan and concurrently analyses the tissue or cell space being scanned. OS-SiA is the trade’s first AI-enabled digital scanner that may present real-time predictive evaluation and actionable insights.

“At the moment, the digital pathology slide scanners are restricted to partial or complete slide picture acquisition and digitization into a picture. Our next-generation scanner OS-SiA scans and analyses concurrently eliminating the necessity for extra processing functions,” mentioned Abhi Gholap, Founder & CEO, OptraSCAN. “This patent highlights our fixed efforts to enhance the adoption of digital pathology options and assist the pathology group.”

OS-SiA could be embedded within the present collection of its cloud-enabled brightfield scanners specifically OS-Lite & OS-Extremely. The customized algorithms present real-time ROI detection whereas scanning, cell quantification for IHC/HNE markers, morphological measurements constructed utilizing the core library. The entire slide picture could be seen in an area/web-based/cloud-based picture viewer. The deep studying computational module is offered for self-learning within the scanning system.

“That is the sort of breakthrough we have to speed up the adoption of digital pathology, simultaneous scanning and evaluation will assist pathologists make quicker choices and enhance affected person outcomes,” Dr. Zu-Hua Gao MD, Medical Advisor at OptraSCAN and Chair – Pathology, College of British Columbia

OptraSCAN and Inspirata Announce Their Technical Partnership to Strengthen Digital Pathology Adoption

OptraSCAN and Inspirata Announce Their Technical Partnership to Strengthen Digital Pathology Adoption

OptraSCAN®, a leading end-to-end digital pathology solution provider announces its partnership with Inspirata Inc., a leading provider of digital pathology and cancer informatics solutions. This partnership will allow pathology labs, healthcare networks and hospitals to acquire digital pathology images without any upfront cost and display them within a world-class workflow solution.

“We are excited to be working with Inspirata to support their mission to digitize and automate the entire oncologic pathology workflow,” said Abhi Gholap, Founder of OptraSCAN. “Our On-Demand scanning model will allow pathologists to digitize their slides without any capital cost,” he further added.

OptraSCAN’s partnership with Inspirata marks the latest extension to its affordable pay-per-use scanning devices. Shared Inspirata and OptraSCAN customers can now utilize native OptraSCAN image files from within Dynamyx™. Facilitating slide digitization at an affordable cost, the seamless integration of OptraSCAN provides:

  • Cloud-based whole slide imaging systems.
  • Flexibility to choose from 15 slides capacity to 480 slides capacity.
  • Well-equipped for confocal, brightfield, fluorescence and frozen section applications.

“Inspirata is delighted to work with its friends at OptraSCAN to accelerate global adoption of digital pathology. OptraSCAN’s status as an approved partner guarantees the seamless integration of its leading whole slide image scanners with Inspirata’s Dynamyx™ digital pathology workflow software,” said Dr Mark Lloyd, Founder and EVP, Inspirata.

“Following our recent successes with Inspirata’s Dynamyx™ digital pathology workflow software in Europe, Fujifilm welcomes this partnership between Inspirata and OptraSCAN,” said Tim Wing, Head of Digital Pathology at Fujifilm Europe. “The OptraSCAN range fits small low volume specialist labs all the way up to high volume multi-site labs and will further increase the options for customers of the Fujifilm Digital Pathology Solution looking to make informed choices regarding scanners that fit their often-unique requirements. OptraSCAN’s digital pathology scanners paired with Inspirata’s open-architecture Dynamyx™ case management platform will allow pathologists to implement digital pathology solutions at economical pricing and enable healthcare providers to arrive at their preferred blend of laboratory and diagnostic technologies.”

OptraSCAN Announces CytoSiA – A Complete Digital Solution For Scanning And Analysis Of Cytology Slides At Affordable Pricing

OptraSCAN Announces CytoSiA – A Complete Digital Solution For Scanning And Analysis Of Cytology Slides At Affordable Pricing

OptraSCAN®, the leading On-Demand Digital Pathology solution provider, today announced its intelligent solution CytoSiA for rapid yet affordable scanning and analyzing of liquid-based cytology slides and pap-smears. It is a complete solution consisting of OptraSCAN’s digital pathology scanner, storage, and powerful artificial intelligence (AI) algorithms to assist pathologists and cytotechnologists in screening and detection of cervical cancer, pre-cancerous lesions, atypical cells, and all other cytologic categories. Multiple hospitals and pathology laboratories globally have already installed CytoSiA and are witnessing improved patient outcomes, increased efficiency, and productivity needed to cope with the ever-increasing demand of cytology cases.

“OptraSCAN is redefining cervical cancer screening by introducing CytoSiA, it offers a plethora of features, to effectively screen liquid-based cytology slides, and pap smears to differentiate between normal and abnormal cervical cells using Bethesda classifications on normal to squamous cell carcinoma (NILM/LSIL/HSIL/SCC)”, said Abhi Gholap, Founder of OptraSCAN. With a range of scanning devices handling as low as 50 slides a week to 5000 slides a week at an extremely affordable price,” he further added.

OptraSCANS’s digital scanners can scan cytology slides of size 15×15 mm area at 40x magnification in less than 60 seconds while generating the highest quality image. CytoSia incorporates patented technology- composite imaging which finds all pixels in focus from various Z plane images and stitches back to create a single layer composite image. This composite imaging technology is considerably efficient as compared to traditional Z-Stacking Technology. It allows for rapid and precise screening of the entire slide within seconds. This level of precision and quality is imperative for analyzing the samples. Furthermore, it presents to the screener images of fields that would be essential in providing a cytological interpretation, place them into categories, and filter out the redundancies.

CytoSiA when used as a companion diagnostic tool, it notifies pathologists when inconsistencies between their interpretation and the AI algorithm’s findings are observed, offering a safeguard against error or misinterpretation, while also improving overall care quality.

Features of CytoSiA:

  • Automated computation of sample adequacy for the whole slide cytology image
  • Identification of abnormal cells and other entities based on morphological features and AI-based classification using Bethesda scoring
  • Identification of reactive, endometrial, actinomyces, candida, clue cells, trichomonas vaginalis, and herpes entities
  • Identification of entities including blood, inflammation, and lubricant

“AI-based image analysis requires images that are of superior quality,” said Dr Aparna Joshi, Medical Director, at OptraSCAN. “Our team has developed an intelligent imaging technology that transforms physical glass cytology slides into digital images with exceptional clarity. Advanced image analysis and standardization are now achievable with this quality of digitization,” she further added.

OptraSCAN Unveils OS-Ultra 320 First Ever High-Speed Scanner at Economical Pricing

OptraSCAN Unveils OS-Ultra 320 First Ever High-Speed Scanner at Economical Pricing

Pune (Maharashtra) [India], April 29 (ANI/BusinessWire India): OptraSCAN®, the leading end-to-end digital pathology solution provider, has announced the launch of OS-Ultra 320, the world’s first-ever affordable high-speed digital pathology scanner.

The OS-Ultra 320 scans tissues/cells of size 15×15 mm area at 40x magnification in less than 60 seconds and features no-touch continuous loading operation. The OS-Ultra 320 is designed to reduce workflow errors and scale-up pathology laboratory operations.

“We are disrupting digital transformation of Pathology and Cytology through affordability,” said Abhi Gholap, founder of OptraSCAN. “With our 15-slide scanner getting tremendous traction for small laboratories, we are happy to launch our high performance 320 slide scanning device at an economical pricing as a complete solution to scan-store-analyze-share the cases,” he further said.

“OS-Ultra 320 represents a significant development in reducing technician time while maintaining perfect image quality for the healthcare professionals. It will provide better performance and improved capabilities,” said Dr Clive Taylor, Chief Medical Officer of OptraSCAN.

OS-Ultra technical specifications:

  • Continuous Slide Loading: Intuitive interface with fully automated walk-away acquisition
  • Light Source: LED
  • Focusing Technique: Real-Time Auto Focus
  • File Format: JPEG2000, TIFF ability to convert file formats
  • Slide Formats: Standard 25x75mm (1″x3″) slides, 50x75mm (2″x3″) slides
  • Slide Tolerances: Length: +- 1mm, Width: +- 1mm, Thickness +- 0.2mm
  • Resolution: 0.25 m /pixel
  • Workflow Software application
  • TELEPath application
  • Image Analysis Suite for Breast, Prostate, Brain, Renal and Lung (IHC and H&E)

OS-Ultra is also available for purchase via partners Nikon USA, FujiFilm and other distributors – https://www.optrascan.com/contact-us

For scheduling demo, please get in touch at ultra@optrascan.com OptraSCAN unveils OS-Ultra 320, first-ever high-speed scanner at economical pricing

OptraSCAN Launches OS-Ultra World’s First High Speed Whole Slide Scanner At Affordable Pricing

OptraSCAN Launches OS-Ultra World’s First High Speed Whole Slide Scanner At Affordable Pricing

SAN JOSE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) – OptraSCAN® , the leading end-to-end digital pathology solution provider, launched OS-Ultra world’s first-ever affordable high-speed whole slide scanner for digital pathology. OS-Ultra scans tissues / cells of size 15×15 mm area at 40x equivalent in less than 60 seconds. OS-Ultra features a unique no-touch slide loading mechanism to diminish workflow errors and produce high resolution images.

“OS-Ultra whole slide scanner provides pathologists with high-quality images within seconds, we are proud to create solutions that empower quicker and improved patient outcomes at cost-effective pricing, said Abhi Gholap, Founder and CEO of OptraSCAN. “Growth of Digital Pathology industry was limited owing to regulatory clearance hurdles and high cost of whole slide scanning devices. I am glad that OptraSCAN is successfully disrupting the pricing model that will further help in higher adoption of Digital Pathology for the benefits of mankind,” he further added.

Abhi Gholap was also co-founder of BioImagene- acquired by Roche in 2010.

OS-Ultra uses patented composite imaging techniques that ensures 0% out of focus regions. Automatic region detection, seamless cloud upload of data while it scans and the ability to integrate image analysis during scanning are some of its additional significant features. OS-Ultra is available with internal loaders for 4 slides, 15 slides, 120 slides and 300 slides capacity. OS-Ultra also features continual slide loading ability unlike many other products in the market, those cannot begin scanning unless all 200 slides are loaded, and door closed. OS-Ultra is economically priced with 24×7 support and services for 99.99% uptime.

For scheduling demo, please get in touch at ultra@optrascan.com

About OptraSCAN, Inc.

OptraSCAN® are pioneers in the On-Demand Digital Pathology® System, focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services. An ISO 13485 certified company and CE marked whole slide scanners for IVD use, OptraSCAN is working to eliminate the barriers to “Go Digital” no matter the size of the pathology lab, the lab’s throughput or global location.

OptraSCAN’s end-to-end digital pathology solution provides effective acquisition of whole slide images, viewing, storing, real-time sharing, reporting and AI & ML based Image analysis solutions via On-Demand or outright purchase model. Follow Us on LinkedIn and Twitter.